Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rivaroxaban

FDA-approved product (tablet, oral), marketed as Rivaroxaban, Xarelto.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Rivaroxaban
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Atrial fibrillation
  • Coronary artery disease
  • Deep vein thrombosis
  • Peripheral arterial disease
  • Pulmonary embolism
  • Recurrent thrombophlebitis
  • Stroke
  • Thrombotic disease
  • Total joint arthroplasty
  • Venous thromboembolism
  • Venous thrombosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Direct factor xa inhibitors
FDA pharmacologic class
Factor Xa Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rivaroxaban in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rivaroxaban with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)

    NCT01710267 · start 2013-03

    Registered record
    Registry ID
    NCT01710267
    Conditions
    Healthy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-03
    Completion
    2014-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty

    NCT01720108 · start 2013-02-24

    Registered record
    Registry ID
    NCT01720108
    Conditions
    Venous Thromboembolism
    Interventions
    rivaroxaban and ASA
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-02-24
    Completion
    2016-07
    Enrolment
    3,426

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    Interventionrivaroxaban and ASA
    PhasePhase 3
    Registry statusCompleted

  • Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

    NCT01499953 · start 2012-04

    Registered record
    Registry ID
    NCT01499953
    Conditions
    Superficial Vein Thrombosis
    Interventions
    Rivaroxaban; Fondaparinux
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-04
    Completion
    2016-05
    Enrolment
    472

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSuperficial Vein Thrombosis
    InterventionRivaroxaban; Fondaparinux
    PhasePhase 3
    Registry statusCompleted

  • Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban

    NCT01436526 · start 2009-08

    Registered record
    Registry ID
    NCT01436526
    Conditions
    Therapeutic Equivalency
    Interventions
    Rivaroxaban (Xarelto, BAY59-7939); Rivaroxaban (Xarelto, BAY59-7939)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-08
    Completion
    2009-09
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTherapeutic Equivalency
    InterventionRivaroxaban (Xarelto, BAY59-7939); Rivaroxaban (Xarelto, BAY59-7939)
    PhasePhase 1
    Registry statusCompleted

  • An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

    NCT00402467 · start 2004-02

    Registered record
    Registry ID
    NCT00402467
    Conditions
    Venous Thromboembolism
    Interventions
    Rivaroxaban (BAY59-7939); Rivaroxaban, (BAY59-7939); Rivaroxaban, (BAY59-7939); Rivaroxaban, (BAY59-7939); Enoxaparine; Enoxaparine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-02
    Completion
    2004-11
    Enrolment
    613

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    InterventionRivaroxaban (BAY59-7939); Rivaroxaban, (BAY59-7939); Rivaroxaban, (BAY59-7939); Rivaroxaban, (BAY59-7939) +2 more
    PhasePhase 2
    Registry statusCompleted